YARW YARW
Company Profile ↓Company Overview
YARW (YARW) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $570.00K (+13.8% YoY); net profit $-26.48M.
- Trailing 12 Months Year-on-year growth — revenue +13.8%.
- 5-Year Trend Long-term compounding — revenue CAGR -1.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -1.84% |
| 1 Year: | 13.77% |
Stock Price Performance
| 1 Year: | +214.81% |
| 6 Months: | +48.36% |
| 3 Months: | +45.26% |
| 1 Month: | -39.99% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)28.88 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -1.8% CAGR over 5 years.
- Trading 40.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 308.00K | 0 | 0 | - | 1.75M | 11.69M | 3.27M | - | 230.00K | 295.00K | 133.00K | 178.00K | 126.00K | 167.00K | 99.00K | 135.00K | 114.00K | 98.00K | 198.00K | 121.00K | 202.00K | 69.00K | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 994.00K | 2.86M |
| Operating Income | - | - | - | - | -5.55M | -6.22M | -8.34M | - | -13.22M | -9.17M | -13.70M | - | -15.88M | -19.36M | -23.20M | -37.43M | -39.89M | -167.18M | -23.49M | -21.99M | -9.76M | -9.54M | -10.77M | -8.69M | -8.29M | -9.33M | -5.88M | -10.32M | -6.23M | -7.38M | -10.40M | -13.09M | -9.20M | -7.54M | -994.00K | -2.86M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -994.00K | -2.86M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -70.99M | -2.75M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.27M | -3.56M | -3.40M | -4.84M | -5.47M | -6.15M | -8.17M | -9.28M | -12.66M | -8.35M | -12.85M | -17.59M | -15.20M | -18.99M | -23.16M | -21.50M | -40.23M | -167.44M | -24.71M | - | -20.55M | -19.92M | -21.29M | 4.67M | -8.48M | -9.46M | -5.62M | -10.06M | -6.58M | -6.25M | -9.41M | -12.16M | -8.61M | -5.75M | -70.99M | -2.75M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.83 | -0.59 | - | -0.42 | -0.39 | -0.41 | 1.51 | -2.63 | -2.94 | -1.74 | -3.09 | -2.01 | -0.15 | -0.22 | -0.29 | -0.20 | -0.13 | - | - |
| R&D Expense | - | - | - | - | 4.99M | 5.46M | 8.01M | - | 11.02M | 16.23M | 10.67M | - | 10.85M | 12.56M | 12.45M | - | 15.95M | 13.12M | 6.62M | - | 4.25M | 5.05M | 5.92M | 4.45M | 4.11M | 5.55M | 2.73M | 7.23M | 3.32M | 3.71M | 7.31M | 10.25M | 6.12M | 4.88M | - | 817.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 674.00K | 4.58M | 3.60M | 443.00K | 20.99M | 931.00K | 477.00K | 424.00K | 501.00K | 570.00K |
| Operating Income | -4.61M | -14.33M | -29.59M | -74.89M | -95.87M | -252.55M | -38.91M | -34.30M | -29.26M | -43.64M | -29.75M |
| Net Income | -4.61M | -14.07M | -29.08M | -74.16M | -95.18M | -255.57M | -73.33M | -23.21M | -28.45M | -39.83M | -26.48M |
| Diluted EPS | - | - | - | - | - | 7.88 | -25.64 | -7.28 | -2.78 | -0.93 | -0.62 |
| R&D Expense | 2.92M | 11.26M | 29.01M | 64.47M | 51.20M | 43.53M | 19.54M | 18.39M | 16.31M | 30.95M | 19.24M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 42.05M | 66.87M | 139.93M | 81.16M | 93.74M | 67.05M | 40.76M | 97.69M | 66.91M | 100.41M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 100.00M |
| Cash & Equivalents | 273.00K | 43.81M | 4.03M | 10.21M | 27.87M | 43.76M | 57.56M | 42.25M | 30.91M | 30.62M | 19.93M | 99.99M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | 0 |
| Total Liabilities | - | - | 12.49M | 14.57M | 9.55M | 63.58M | 56.25M | 18.41M | 9.35M | 8.95M | 14.82M | 71.55M |
| Current Liabilities | - | - | 3.90M | 7.82M | 9.54M | 29.33M | 21.77M | 18.41M | 9.35M | 7.54M | 14.82M | 71.55M |
| Long Term Debt | - | - | - | - | - | 32.73M | 33.17M | 0 | 0 | 0 | 0 | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Equity | -11.41M | -15.95M | -29.44M | 68.60M | 92.18M | 17.57M | 37.49M | 48.64M | 31.20M | 88.73M | 52.09M | 28.86M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.18M | -2.27M | -28.22M | -68.66M | -73.39M | -137.08M | -56.37M | -29.20M | -25.34M | -33.97M | -33.12M |
| Investing Cash Flow | 0 | -37.52M | -15.09M | -11.76M | 41.87M | 89.11M | 1.03M | 15.67M | -57.35M | 23.36M | 37.37M |
| Financing Cash Flow | 47.72M | 0 | 49.49M | 92.37M | 47.95M | 61.81M | 39.78M | 1.65M | 82.39M | -141.00K | -143.00K |
| Capital Expenditure | -0 | -31.00K | -27.00K | -567.00K | -1.06M | -113.00K | -0 | - | - | - | - |
| Free Cash Flow | -4.18M | -2.30M | -28.25M | -69.23M | -74.45M | -137.19M | -56.37M | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -2,126.4% | -645.9% | -2,083.2% | -21,641.8% | -1,203.0% | -4,179.5% | -7,189.7% | -6,900.5% | -8,710.0% | -5,219.1% |
| Net Margin % | - | -2,087.2% | -634.6% | -2,062.9% | -21,484.9% | -1,217.4% | -7,876.4% | -4,865.8% | -6,710.4% | -7,950.9% | -4,646.1% |
| ROE % | 28.9% | 47.8% | -42.4% | -80.5% | -541.6% | -681.6% | -150.8% | -74.4% | -32.1% | -76.5% | -91.8% |
| ROCE % | - | -37.6% | -50.1% | -57.4% | -185.0% | -350.9% | -80.0% | -109.2% | -32.5% | -83.8% | -103.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Adar1 Capital Management, LLC | 2.21% | 59.00K | $2.18M |
| 2 | Staley Capital Advisers, Inc. | 1.93% | 51.47K | $1.90M |
| 3 | Nantahala Capital Management, LLC | 1.50% | 40.00K | $1.48M |
| 4 | Lynx1 Capital Management Lp | 1.22% | 32.57K | $1.21M |
| 5 | Shay Capital LLC | 1.09% | 29.13K | $1.08M |
| 6 | T3 Companies, LLC | 0.71% | 18.90K | $699.30K |
| 7 | Braidwell LP | 0.69% | 18.32K | $677.91K |
| 8 | Kvp Capital Advisors, LP | 0.37% | 10.01K | $370.41K |
| 9 | Citadel Advisors Llc | 0.35% | 9.37K | $346.65K |
| 10 | Two Sigma Investments, LP | 0.33% | 8.78K | $324.71K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for YARW
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
NEW HAVEN, Conn., September 14, 2026--Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced…
Yarrow Bioscience Announces Proposed Underwritten Public Offering
NEW HAVEN, Conn., September 10, 2026--Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced…
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
NEW HAVEN, Conn., September 11, 2026--Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced…
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
NEW HAVEN, Conn., August 13, 2026--Yarrow Bioscience reports second quarter 2026 financial results and provides a business update.
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease
NEW HAVEN, Conn., July 27, 2026--Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the …
YARW — Frequently Asked Questions
What is the current share price of YARW?
As of 2026-09-16 18:39 PDT, YARW trades at $25.50 on NASDAQ/NYSE. Its 52-week range is $8.10 to $42.94.
What is the P/E ratio of YARW?
YARW trades at a trailing price-to-earnings (P/E) ratio of -41.13.
What is the return on equity (ROE) of YARW?
YARW has a return on equity (ROE) of -91.76%. Its return on capital employed (ROCE) is -103.08%.
Is YARW a good stock to buy?
This page provides a data-driven analysis of YARW, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.